Abstract：Objective To investigate the clinical effect of Metoprolol Succinate Sustained-release Tablets in the treatment of dilated cardiomyopathy. Methods A total of 74 patients with dilated cardiomyopathy who were admitted to our hospital from April 2018 to April 2019 were selected as the observation objects. According to the random number table method, the patients were divided into the conventional group (n=37, treated with Sacubitril Valsartan Sodium Tablets)and the study group (n=37, treated with Metoprolol Succinate Sustained-release Tablets on the basis of the conventional group). The heart rate (HR), left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter(LVESD), and the number of pre-ventricular contractions in 24 h before and after treatment were observed and compared between the two groups and the incidence of arrhythmias and major adverse cardiac events (MACE) was compared between the two groups after 6 months of follow-up. Results After treatment, the HR, LVEDD and LVESD in the study group were lower than those in the conventional group, and the number of pre-ventricular contractions in 24 h in the study group was fewer than that in the conventional group, with statistically significant differences (P＜0.05). Following up for 6 months, the total incidence rates of arrhythmia and MACE in the study group were lower than those in the conventional group, with statistically significant differences (P＜0.05). Conclusion The use of Metoprolol Succinate Sustained-release Tablets in the treatment of dilated cardiomyopathy can effectively reduce the occurrence of arrhythmia, acute heart failure and other adverse events, improve the cardiac function of patients, and improve the long-term efficacy of patients.
京公网安备 11010502046607号